Boston Scientific (BSX) Gets Favorable Ruling in Patent Case with J&J (JNJ)
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Join SI Premium – FREE
Boston Scientific Corporation (NYSE: BSX) announces that the U.S. District Court for the District of New Jersey has found all the asserted patents in a suit brought by Johnson & Johnson (NYSE: JNJ) to be invalid and entered judgment in favor of Boston Scientific.
As part of a 2008 suit, Johnson & Johnson alleged that Boston Scientific's PROMUS® Everolimus-Eluting Coronary Stent System infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146 (known as "the Morris patents"). The patents relate to the use of a drug on a drug-eluting stent.
As part of a 2008 suit, Johnson & Johnson alleged that Boston Scientific's PROMUS® Everolimus-Eluting Coronary Stent System infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146 (known as "the Morris patents"). The patents relate to the use of a drug on a drug-eluting stent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Gray Media closes $750M note offering to refinance higher-rate debt
- Sigma Lithium resumes full operations after signing TAC agreement
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
